Scarica l'app Stockscreener
32.65
4.29%
-1.615
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BEAM Giù?
Forum
Previsione
Precedente Chiudi:
$34.26
Aprire:
$33.98
Volume 24 ore:
513.12K
Relative Volume:
0.25
Capitalizzazione di mercato:
$3.31B
Reddito:
$352.57M
Utile/perdita netta:
$-143.01M
Rapporto P/E:
-18.04
EPS:
-1.81
Flusso di cassa netto:
$-153.40M
1 W Prestazione:
+5.03%
1M Prestazione:
+18.08%
6M Prestazione:
+47.97%
1 anno Prestazione:
+24.72%
Intervallo 1D:
$32.65
$35.05
Intervallo di 1 settimana:
$29.80
$35.34
Portata 52W:
$13.53
$36.44
Beam Therapeutics Inc Stock (BEAM) Company Profile
Nome
Beam Therapeutics Inc
Settore
Industria
Telefono
857-327-8775
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Confronta BEAM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
32.65 | 3.48B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.46 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.71 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
823.85 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.67 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.31 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-09 | Iniziato | Jefferies | Buy |
| 2025-03-28 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-03-10 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-07-23 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-08 | Downgrade | Jefferies | Buy → Hold |
| 2023-10-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | Iniziato | Citigroup | Buy |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2022-01-05 | Iniziato | Guggenheim | Buy |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-09-24 | Ripresa | Stifel | Buy |
| 2021-09-10 | Iniziato | BofA Securities | Buy |
| 2021-05-11 | Iniziato | Redburn | Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-02-16 | Iniziato | Wells Fargo | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-08-05 | Iniziato | William Blair | Outperform |
| 2020-03-02 | Iniziato | Barclays | Overweight |
| 2020-03-02 | Iniziato | JP Morgan | Overweight |
| 2020-03-02 | Iniziato | Jefferies | Buy |
| 2020-03-02 | Iniziato | Wedbush | Outperform |
Mostra tutto
Beam Therapeutics Inc Borsa (BEAM) Ultime notizie
William Blair Maintains Beam Therapeutics(BEAM.US) With Buy Rating - 富途资讯
Cathie Wood Sells Beam Therapeutics Stock, Buys WeRide and Tempus AI - Blockonomi
Cathie Wood Sells $5 Million Beam Therapeutics Stock, Buys WeRide and Tempus AI - CoinCentral
Campbell & CO Investment Adviser LLC Lowers Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Is Beam Therapeutics Inc forming a breakout pattern2025 Key Highlights & Free Community Consensus Stock Picks - baoquankhu1.vn
Can Beam Therapeutics Inc sustain its profitabilityEarnings Trend Report & Reliable Price Breakout Alerts - baoquankhu1.vn
cathie wood’s ARK sells beam therapeutics stock, buys weride and tempus ai By Investing.com - Investing.com India
cathie wood’s ARK sells beam therapeutics stock, buys weride and tempus ai - Investing.com
Beam Therapeutics (NASDAQ:BEAM) Trading 11.1% HigherWhat's Next? - MarketBeat
Cathie Wood Dumps Beam Therapeutics, Loads Up on Netflix Stock - Blockonomi
Cathie Wood’s ARK ETFs Buy Netflix, Sell Beam Therapeutics in Latest Moves - CoinCentral
Insider Sell: Bethany Cavanagh Sells Shares of Beam Therapeutics Inc (BEAM) - GuruFocus
Beam Therapeutics (BEAM) Receives Rating Update with Raised Pric - GuruFocus
Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway By Investing.com - Investing.com India
Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway - Investing.com Nigeria
Discipline and Rules-Based Execution in BEAM Response - Stock Traders Daily
Insider Selling: Beam Therapeutics (NASDAQ:BEAM) Insider Sells 18,629 Shares of Stock - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 6.1%Should You Sell? - MarketBeat
Earnings Report: Is Beam Therapeutics Inc a cyclical or defensive stock2025 EndofYear Setup & Accurate Intraday Trade Tips - baoquankhu1.vn
Aug Intraday: What is Rapid7 Incs 5 year growth outlookPortfolio Return Summary & Consistent Growth Equity Picks - baoquankhu1.vn
Beam Therapeutics stock maintains Buy rating at H.C. Wainwright on FDA alignment - Investing.com Nigeria
Gene editing trials in sickle cell advance as Beam builds $1.1B cash - Stock Titan
Institution Moves: Will BHRPRD announce a stock splitPortfolio Risk Report & Weekly Return Optimization Plans - baoquankhu1.vn
Bernstein Keeps Their Buy Rating on Beam Therapeutics (BEAM) - The Globe and Mail
Sumitomo Mitsui Trust Group Inc. Has $117.24 Million Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
BEAM: Base editing programs advance toward approval, backed by strong data, funding, and scalable technology - TradingView — Track All Markets
BEAM: Predictable gene editing advances drive pivotal programs and commercial readiness into 2029 - TradingView — Track All Markets
Buyback Watch: How does AHTPRI score in quality rankingsQuarterly Market Summary & Growth Focused Entry Point Reports - baoquankhu1.vn
BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises - sharewise.com
Beam Therapeutics: Pivoting From Platform To Execution Stage (NASDAQ:BEAM) - Seeking Alpha
April 17th Options Now Available For Beam Therapeutics - Nasdaq
Beam Therapeutics (BEAM) to Submit Biologics License Application for Risto-cel by End of 2026 - Intellectia AI
Beam Therapeutics (BEAM) Valuation After FDA Alignment And Extended Cash Runway To 2029 - Yahoo Finance
Beam Therapeutics stock today: BEAM edges lower premarket after FDA alignment sparks 22% rally - TechStock²
Beam Therapeutics (NASDAQ:BEAM) Reaches New 1-Year HighStill a Buy? - MarketBeat
Beam Therapeutics Price Target Upgrade Signals Positive Outlook - timothysykes.com
Gene Editor Soars To 10-Month High On Bullish FDA News - Investor's Business Daily
Beam Therapeutics (NASDAQ:BEAM) Shares Gap UpTime to Buy? - MarketBeat
Beam Therapeutics stock maintains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Nigeria
Key facts: Beam Therapeutics seeks FDA approval for BEAM-302 therapy - TradingView — Track All Markets
Beam Therapeutics Stock Surges: What's Driving The Sudden Jump? - Benzinga
Beam Therapeutics (BEAM) Shares Surge Nearly 28% - GuruFocus
Beam Therapeutics stock maintains Overweight rating at Cantor Fitzgerald - Investing.com
BEAM Stock In Focus As FDA Alignment Wins William Blair’s Praise - Stocktwits
Beam Therapeutics Advances Genetic, Hematology Pipeline, Extends Cash Runway to 2029; Shares Rise - marketscreener.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Beam Therapeutics (BEAM) Sees Positive Developments in Regulator - GuruFocus
Beam Therapeutics higher after reaching FDA alignment on BEAM-302 - TipRanks
Beam Therapeutics (BEAM) Eyes Accelerated FDA Approval for BEAM-302 - GuruFocus
Beam Therapeutics (BEAM) Shares Soar on Strategic Advances - GuruFocus
Beam Therapeutics (BEAM) Shares Surge Over 23% in Recent Trading - GuruFocus
Beam Therapeutics Inc Azioni (BEAM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.36%
2.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):